Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.54 USD | -2.78% | -2.29% | +44.04% |
06-04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
06-03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.04% | 2.38B | |
-24.29% | 7.61B | |
+7.64% | 6.63B | |
+15.67% | 5.53B | |
-15.51% | 4.89B | |
+16.83% | 4.17B | |
-21.75% | 3.99B | |
-23.04% | 2.88B | |
+1.24% | 2.08B | |
+10.67% | 1.99B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Earnings Flash (NVCR) NOVOCURE Reports Q3 Revenue $127.3M, vs. Street Est of $128.8M